Tsis ntev los no, Hefei Livzon Pharmaceutical Co., Ltd. (tom qab no hu ua "Company" lossis "Livzon Pharmaceutical") tau txais "Acceptance Notification" los ntawm National Medical Products Administration (NMPA) rau Daim Ntawv Tso Cai Ua Lag Luam (MAA) ntawm Dexmethylphenidate Hydrochloride Active Pharmaceu (MAA)API). Cov ntsiab lus tseem ceeb tau tshaj tawm hauv qab no:
I. Cov ntsiab lus tseem ceeb ntawm "Kev Ceeb Toom Txais"
Daim Ntawv Thov: Kev Tso Cai Ua Lag Luam
Khoom npe: Dexmethylphenidate Hydrochloride
Kev lees paub piav qhia: Raws li Tshooj 32 ntawm "Txoj Cai Tswjfwm Kev Cai Lij Choj ntawm Cov Neeg Suav Tebchaws Suav", tom qab tshuaj xyuas, nws txiav txim siab lees txais daim ntawv thov.
Tus Naj Npawb: Y20240001340 (Acceptance Number: CXHS2460***)
II. Cov ntaub ntawv ntsig txog Dexmethylphenidate Hydrochloride
Dexmethylphenidate Hydrochloride yog lub hauv paus paj hlwb stimulant qhia rau kev kho mob ntawm Attention Deficit Hyperactivity Disorder (ADHD). Tsim los ntawm Celgene Corporation ntawm Tebchaws Meskas, tsis muaj qhov cuam tshuam rau daim ntawv ua tiav cov khoom ntawm cov tshuaj no tau pom zoo rau kev lag luam hauv Suav teb txij li hnub tshaj tawm no. Tshwj tsis yog rau Lub Tuam Txhab, ib lub tuam txhab tau ua tiav daim ntawv sau npe thiab ua tiav API no, nrog rau cov xwm txheej sau npe cim "Kuv" (Cov Khoom Siv Tshuaj Siv Tshuaj / Cov Khoom Siv Khoom Siv / Cov Khoom Siv Ntim uas tseem tsis tau dhau qhov kev tshuaj xyuas thiab kev pom zoo nrog rau daim foos tiav lawm).
